Gossamer Bio (GOSS) Company Overview

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February.

We have put together a list of the 12 Best Penny Stocks to Invest in Based on Media Recommendations. In this article, we will examine how Gossamer Bio, Inc. (NASDAQ:GOSS) compares to other top penny stocks suggested by the media. Additionally, we will discuss the outlook for small-cap stocks in 2025.

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago.

Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.

Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025.